TScan Therapeutics Announces Launch Of Proposed Public Offering; No Size Disclosed
Portfolio Pulse from Happy Mohamed
TScan Therapeutics (NASDAQ:TCRX) has announced the launch of a proposed public offering of voting common stock, non-voting common stock, and pre-funded warrants. The offering is subject to market, regulatory, and other conditions. Morgan Stanley and Wedbush PacGrow are acting as joint book-running managers.
May 25, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TScan Therapeutics is launching a public offering of common stock and pre-funded warrants, which may impact its stock price in the short term.
The announcement of a public offering can have mixed effects on a company's stock price. While it may lead to an increase in capital, it can also dilute existing shares. The impact on TCRX's stock price will depend on the market's reaction to the offering and the actual size and terms of the offering, which are not yet disclosed.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100